RNA has breathtaking capabilities as therapeutic agent, as biopesticide or as functional molecule in cosmetics. Short sequences such as anti-oligos and siRNA are easily produced by chemical synthesis. Long sequences, as needed for mRNA therapy or dsRNA-based biopesticides, require biotechnological processes such as in vitro transcription. However, current in vitro transcription methods are neither scalable nor cost-effective.
SenseUp is currently developping a novel plattform, for in vivo production of long RNA, enabling unlimited scalability and dramatically reduced production costs compared to in vitro transcription.